The US Food and Drug Administration (FDA) has granted Dicot Pharma approval to roll out the Phase IIb study of a treatment for erectile dysfunction.  The approval follows an Investigational New Drug (IND) Application submitted to the FDA, with the trial evaluating LIB-01 now set to commence in the US.  Dicot Pharma says LIB-01 will be a potency agent […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!